Cross-talk related to insulin and angiotensin II binding on myocardial remodelling in diabetic rat hearts

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 8, Issue 2, 2007, Pages 59-65

  Maharsy, Wael M ^a   Kadi, Lina N ^a   Issa, Nahla G ^a   Bitar, Khalil M ^a   Der Boghossian, Asdghig H ^a   Abrahamian, Roy ^a   Bikhazi, Anwar B ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Angiotensin ll receptors; Cardiomyopatny; Insulin receptor; Insulin dependent diabetes mellitus; Receptor regulation

Indexed keywords

3 [(3 CHOLAMIDOPROPYL)DIMETHYLAMMONIO] 1 PROPANESULFONIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; BOVINE INSULIN; LOSARTAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BODY WEIGHT; CARDIOVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIUM CELL; ENZYME REGULATION; GLUCOSE BLOOD LEVEL; HEART MUSCLE CELL; HEART PERFUSION; HEART WEIGHT; MALE; MONOTHERAPY; NONHUMAN; PROTEIN BINDING; RAT; RECEPTOR BINDING; RECEPTOR DENSITY; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; WESTERN BLOTTING;

ANGIOTENSIN II; ANIMALS; ANTI-ARRHYTHMIA AGENTS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; HEART; INSULIN; LOSARTAN; MYOCARDIAL INFARCTION; ORGAN SIZE; RATS; RECEPTOR CROSS-TALK; RECEPTOR, INSULIN; RECEPTORS, ANGIOTENSIN; REFERENCE VALUES;

EID: 34547976750     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2007.011     Document Type: Article

References (36)

1. Clauser E. Synthesis and local and distant actions of vasoactive peptides. Annales d Endocrinologie 2000;61:10-15.
2. De Mello W, Danser AH. Angiotensin II and the heart: on the intracrine renin-angiotensin system. Hypertension 2000;35:1183-8.
3. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000;52(1):11-34.
4. Schwartz F, Duka A, Duka I, Cui J, Gavras H. Novel targets of ANG II regulation in mouse heart identified by serial analysis of gene expression. Am J Physiol Heart circ Physiol 2004; 287:H1957-H1966.
5. 2+ modulation. Circ Res 1996; 78:302-11.
6. Clauser E. Molecular structure and function of angiotensin ii receptors. Nephrologie 1998;19:403-10.
7. Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, Kahn CR. Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA 1996;93:12490-5.
8. Conchon S, Miserey S, Parnot C, Monnot C, Corvol P, Clauser E. Several interesting phenotypes of the AT1 receptor produced by site-directed mutagenesis. J Am Soc Nephrol 1999;10(suppl 11):S8-S14.
9. Nouet S, Amzallag N, Li JM et al. Trans-inactivation of receptor tyrosine kinases by novel angiotensin II AT2 receptor-interacting protein, ATIP. J Biol Chem 2004;279:28989-97.
10. Anavekar NS, Solomon SD. Angiotensin II receptor blockade and ventricular remodelling. JRAAS 2005;6(1):43-8.
11. Ritter O, Schuh K, Brede M, Rothlein N, Burkard N, Hein L, Neyses L. AT2 receptor activation regulates myocardial eNOS expression via the calcineurin-NF-AT pathway FASEB J 2003;17:283-5.
12. Broxmeyer L. Diabetes mellitus, tuberculosis and the mycobacteria: two millenia of enigma. Med Hypotheses 2005;65:433-9.
13. Connelly K, Kelly D, Langham R, Krum H, Gilbert RE. Drug therapy for the cardiac complications of diabetes. Drug Discov Today 2004; 1:195-200.
14. Sander GE, Wilklow FE, Giles TD. Heart failure in diabetes mellitus: causal and treatment considerations. Minerva Cardioangiol 2004; 52:491-503.
15. Sylvia BV. Endocrinology and the Heart. In: Crawford MH, editor. Current diagnosis & treatment in cardiology 2nd ed. New York: McGraw Hill; 2003 [cited 2007, February 12] available from http://viww.accessmedicine.com.
16. Al Jaroudi WA, Nuwayri-Salti N, Usta JA. Effect of insulin and angiotensin II receptor subtype-1 antagonist on myocardial remodelling in rats with insulin-dependent diabetes mellitus. J Hypertens 2005;23:381-92.
17. Wang P, Almahfouz A, Giorgino F, McCowen K, Smith R. In vivo insulin signaling in the myocardium of streptozotocin-diabetic rats: opposite effects of diabetes on insulin stimulation of glycogen synthase and c-Fos. Endocrinology 1999;140:1141-50.
18. Velloso LA, Folli F, Perego L, Saad MJ. The multi-faceted cross-talk between the insulin and angiotensin II signaling systems. Diabetes Metab Res Rev 2006;22:98-107.
19. Elbaz N, Bedecs K, Masson M, Sutren M, Strosberg AD, Nahmias C. Functional trans-activation of insulin receptor kinase by growth inhibitory angiotensin II AT2 receptor. Mol Endocrinol 2000; 14:795-804.
20. Berk BC. Angiotensin II signal transduction in vascular smooth muscle: pathways activated by specific tyrosine kinases. J Am Soc Nephrol 1999; 10(suppl 11): S62-S68.
21. Fiordaliso F, Li B, Latini R, Sonnenblick EH, Anversa P, Leri A, Kajstura J. Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II-dependent. Lab Invest 2000;80:513-27.
22. Karam CN, Nuwayri-Salti N, Usta JA et al. Effect of systemic insulin and angiotensin II receptor subtype-1 antagonist on endothelin-1 receptor subtype(s) regulation and binding in diabetic rat heart. Endothelium 2005;12:225-31.
23. Masaki T. The discovery of endothelins. Cardiovasc Res 1998; 39:530-3.
24. Teerlink JR. Reversal of left ventricular remodeling: role of the endothelin pathway. J Card Fail 2002;8:S494-S499.
25. D'Uscio LV, Shaw S, Barton M, Luscher TF. Losartan but not verapamil inhibits angiotensin II - induced tissue endothelin-1 increase. Role of blood pressure and endothelial function. Hypertension 1998; 31:1305-10.
26. Hopfner RL, McNeill JR, Gopalakrishnan V. Plasma endothelin-1 levels and vascular responses at different temporal stages of streptozotocin diabetes. Eur J Pharmacol 1999;374:221-7.
27. Folli F, Kahn R, Hansen H, Bouchie J, Feener P. Angiotensin II inhibits signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997;100:2158-69.
28. Jiang ZY, Zhou Q, Chatterjee A et al. Endothelin-1 modulates insulin signaling through phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells. Diabetes 1999;48:1120-30.
29. Bikhazi AB, Khalifeh AM, Jaroudi WA et al. Endothelin-1 receptor subtypes expression and binding in a perfused rat model of myocardial infarction. Comp Biochem Physiol C Toxicol Pharmacol 2003; 134(1):35-43.
30. Graiani G, Lagrasta C, Migliaccio E et al. Genetic deletion of the p66Shc adaptor protein protects from angiotensin II-induced myocardial damage. Hypertension 2005;46:433-40.
31. 1-receptor expression and potentiate ANG II-induced proliferation in VSM cells. Am J Physiol Heart Circ Physiol 2003; 284:H846-H852.
32. Wassmann S, Nickenig G. Pathophysiological regulation of the AT1-receptor and implications for vascular disease. J Hypertens 2006;24(1):S15-S21.
33. Li C, Cao L, Zeng Q. Astragalus prevents diabetic rats from developing cardiomyopathy by downregulating angiotensin II type 2 receptors' expression. J Huazhong Univ Sci Technolog Med Sci 2004; 24:379-84.
34. Sechi LA, Griffin CA, Schambelan M. The cardiac renin-angiotensin system in STZ-induced diabetes. Diabetes 1994;43:1180-4.
35. Amiri F, Garcia R. Renal angiotensin II receptors and protein kinase C in diabetic rats: effects of insulin and ACE inhibition. Am J Physiol Renal Physiol 2000;278:F603-F612.
36. Chen X, Cui Z, Zhang F, Chang W, Chen L, Liu L. Angiotensin II and cAMP regulate AT(1)-mRNA expression in rat cardiomyocytes by transcriptional mechanism. Eur J Pharmacol 2002;448(1):1-9.